Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has lost $0.0286 (6.10%) and  sits at $0.44, as of 11:37:57 est on June 22.

37,106 shares exchanged hands.

The Company has fallen 4.56% over the last 5 days and shares have fallen 16.17% over the last 30 days.

Galmed expects its next earnings on 2022-08-04.

For technical charts, analysis, and more on Galmed visit the company profile.

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.It is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and plan to initiate a first in human study by the first quarter of 2021.

To get more information on Galmed Pharmaceuticals Ltd and to follow the company's latest updates, you can visit the company's profile page here: Galmed Pharmaceuticals Ltd's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan

'Goldilocks' Stocks Will Define This Decade

What You Need To Know About Bear Markets

Is Your iPhone Already Obsolete?